Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients

NCT01730768 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01730768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01730768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2012
Completion date
December 31, 2013
Enrollment
147 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia